SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.Retry

Cardano

Cardano (ADA) is trending amidst a fiercely divided community, with a dominant sentiment expressing alarm over potential "rugpulls" and significant market "dumps," frequently targeting the project's founder. While many users label ADA a "scam" or "worthless," a contrasting cohort views current price levels as a prime accumulation phase, anticipating a future market surge. This intense divergence in sentiment fuels a heated debate over ADA's immediate outlook.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending after its recent Q3 earnings report, which indicated substantial improvements in net loss and operating cash flow, along with projections for positive revenue trends into 2026. This operational update, alongside news of its CEO increasing focus on the company and ongoing discussions about a potential tZERO public listing, fuels a sharp debate among investors; some see a turnaround, while others remain skeptical about sustained profitability and past shareholder dilution.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is trending following news of its OxyChem unit's sale to Berkshire Hathaway for $9.7 billion. This strategic divestiture is sparking widespread debate among investors, with some viewing it as a crucial step for debt reduction and increased focus on its core oil and gas operations. Conversely, many are questioning the deal's valuation and its long-term impact on the company's diversification, especially given Warren Buffett's significant and evolving stake in the energy producer.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics (UTHR) is trending strongly after positive TETON-2 study results for its Tyvaso DPI in Idiopathic Pulmonary Fibrosis, which analysts suggest could open a substantial market opportunity. The community is actively discussing the recent FDA decision to grant only tentative approval to a competing product, effectively delaying its market entry due to Tyvaso DPI's exclusivity. This development underscores UTHR's dominant market position and robust pipeline, including ongoing advancements in xenotransplantation.

Gold.com, Inc. engages in the trading of gold, silver, platinum, and palladium bullion numismatic coins, and related products. It operates through the following segments: Wholesale Trading and Ancillary Services, Direct-to-Consumer, and Secured Lending. The Wholesale Trading and Ancillary Services segment is involved in the distribution and purchasing of metal products from sovereign and private mints. The Direct-to-Consumer segment provides access to a multitude of products through its wholly owned subsidiaries. The Secured Lending segment includes coin and precious metal dealers, investors, and collectors. The company was founded by Steven C. Markoff on April 9, 1965 and is headquartered in El Segundo, CA.

Gold.com Inc.

Gold, the commodity, is experiencing a historic rally, reaching new all-time highs and igniting widespread investor interest. The community is actively discussing fundamental drivers for this surge, citing central bank buying, strong industrial demand, and evolving monetary policy expectations. This market momentum for the precious metal is directly drawing attention to Gold.com Inc., as its stock sees increased engagement amidst the sector's robust performance.

Listed Funds Trust - Teucrium 2x Long Daily XRP ETF

The Teucrium 2x Long Daily XRP ETF

XXRP is trending amid heightened anticipation for potential Spot XRP ETF approvals and recent legislative efforts to clarify crypto regulations, fueling strong community conviction in XRP's institutional future. Despite its noted volatility and magnified price swings, investors are actively "buying the dip" and using the 2x leveraged ETF as a high-potential vehicle for amplified returns, expecting substantial growth as XRP integrates into global finance.

Sangoma Technologies Corp. engages in the provision of value-based Communications as a Service (CaaS) solutions for businesses. Its services include Unified, Trunking, Contact Center, Communications Platform, Video Meetings, and Collaboration. The company was founded by David Mandelstam in 1984 and is headquartered in Markham, Canada.

Sangoma Technologies Corporation

Sangoma Technologies is drawing attention after significantly exceeding its fiscal year debt reduction goals and initiating a Normal Course Issuer Bid, reflecting strong financial management and a commitment to shareholder returns. Despite recent mixed earnings reports and updated guidance, the community remains actively engaged, with many viewing current levels as a buying opportunity and anticipating a potential breakout driven by increased trading volume.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending after receiving a landmark FDA approval for Yartemlea, making it the first and only approved treatment for transplant-associated thrombotic microangiopathy (TA-TMA) in both adult and pediatric patients. Investors are actively discussing the substantial upside potential, anticipating analyst upgrades and potential acquisition interest, particularly from existing partner Novo Nordisk, as the company is now poised for commercialization and strengthened by its non-dilutive financing.

EHang Holdings Ltd. engages in the provision of aerial vehicle technology platform company. It also provides unmanned aerial vehicle (UAV) systems and solutions: air mobility (including human transportation and logistics), smart city management, and aerial media solutions. The firm operates through the following geographical segments: P.R.C., West Asia, East Asia, South America, Europe, and Other. The company was founded by Huazhi Hu and Yifang Derrick Xiong in December 2014 and is headquartered in Guangzhou, China.

EHang Holdings Ltd - ADR

EHang Holdings

EHang is trending following its recent earnings report, which included a notable cut to full-year revenue guidance, sparking concerns among investors already frustrated by the stock's prolonged stagnation. Despite this, community discussion emphasizes the company's continued operational expansion, new product launches like the VT35, and ongoing international partnerships for its certified pilotless eVTOLs. Many believe EHang remains undervalued given its pioneering technology and robust government backing in China's burgeoning urban air mobility sector.

American Electric Power Co., Inc. engages in the generation, transmission, and distribution of electricity. It operates through the following segments: Vertically Integrated Utilities, Transmission and Distribution Utilities, AEP Transmission Holdco, and Generation and Marketing. The Vertically Integrated Utilities segment covers the generation, transmission, and distribution of electricity for sale to retail and wholesale customers. The Transmission and Distribution Utilities segment represents the transmission and distribution of electricity for sale to retail and wholesale customers. The AEP Transmission Holdco segment comprised of the development, construction, and operation of transmission facilities through investments in its wholly-owned transmission subsidiaries and joint ventures. The Generation and Marketing segment consists of the non-regulated generation and marketing, risk management, and retail activities. The company was founded on December 20, 1906 and is headquartered in Columbus, OH.

American Electric Power Company Inc.

American Electric Power (AEP) is trending as the utility sector experiences record electricity demand, primarily driven by the surging growth of AI-powered data centers and broader electrification efforts. The company's massive multi-billion dollar capital investment plans in grid modernization and renewables aim to meet this demand, positioning it as a key infrastructure play in the AI revolution. Community discussions highlight AEP's potential as a unique growth opportunity within a traditionally defensive sector, with some noting recent oversold conditions as a potential entry point.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuron (IMRN) CEO Steven Lydeamore stated in a letter to shareholders on Thursday that the company does not anticipate any material impact from the recently announced U.S. tariffs on pharmaceutical products.Nasdaq-listed shares of Immuron rallied 8% on Thursday morning following the news. The CEO <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160195/37134/en/Immuron-Letter-to-Shareholders-Projects-Update.html">stated</a> that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs.The Australia-based company also said that it is on track to exceed FY24 first-quarter (Q1) sales. The company is slated to report its Q1 FY25 sales in mid-October.Immuron has three therapeutic products under development, including IMM-124E, also known as Travelan, for traveler’s diarrhea. The company stated that it continues to expect trial results for this candidate in October 2025.“It is hoped that this trial will enable Travelan to be recommended in traveler’s diarrhea guidelines, thereby increasing its market potential,” the company said.As for IMM-529, which is under development for Clostridioides difficile infection, Immuron stated that it is progressing with an application to the U.S. Food and Drug Administration to initiate clinical development by mid-October. According to Immuron, the IMM-529 market in the U.S. is expected to reach peak revenues of approximately $400 million.The company has also advanced the launch of ProIBS, a medical product for treating symptoms related to Irritable Bowel Syndrome, to the fourth quarter from its previous estimate of Q1 2026. Immuron now anticipates a limited launch in Q4, with a full launch in Q1 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/IMRN">IMRN stock</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume improved from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:574/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_12_28_03_PM_png_c36282e1fb.webp" alt="IMRN's Sentiment Meter and Message Volume as of 12:28 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="574" height="58"><figcaption>IMRN's Sentiment Meter and Message Volume as of 12:28 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the company’s updates.<stembedurl>https://stocktwits.com/Timtheshark/message/630768842</stembedurl>IMRN stock is up 22% this year but down approximately 24% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-reports-7-percent-rise-in-q3-deliveries/chCrXlDR3Ow">Tesla’s Q3 Deliveries Hit Quarterly Record, Rise 7% To Exceed Analyst Estimates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 

Equity

CEO Steven Lydeamore stated that while Travelan is imported into the U.S. from Australia, it is not a pharmaceutical product but a dietary supplement, and is therefore not expected to be impacted by U.S. pharmaceutical tariffs. 


Immuron Ltd. is a biopharmaceutical company, which focuses on the development and commercialization of a novel class of specifically targeted polyclonal antibodies. It operates through the Hyper-immune Products and Research and Development (R&D) segments. The Hyper-immune Products segment includes income and expenses directly attributable to Travelan and Protectyn activities. The Research and Development segment refers to the group’s R&D projects performed in Australia and United States. The company was founded on January 13, 1994, and is headquartered in Blackburn, Australia.

IMRN
IMMURON Ltd/S ADR

Feed

News

Sentiment

Fundamentals

Info

Latest IMRN News

IMRNIMMURON Ltd/S ADR